| ||||||||||||||
|
|
|||||||||||||




Departments for *Anesthesia and
Thoracic and Cardiovascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany;
Department of Cardiology, Flinders Medical Center, South Australia, Australia; and
Department of Cardiothoracic Anesthesia, Virginia Commonwealth University, Richmond, Virginia
Address correspondence and reprint requests to Dr. Andreas Koster, Deutsches Herzzentrum Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany. Address e-mail to koster{at}dhzb.de
IMPLICATIONS: Bivalirudin is a new, direct thrombin inhibitor. We investigated the extracorporeal elimination rate of different hemofilters and one plasmapheresis filter for bivalirudin. Our data show that bivalirudin can be effectively eliminated via hemofiltration and plasmapheresis, although there were significant differences in the elimination rates among the filter systems investigated.
This article has been cited by other articles:
![]() |
I. Apostolidou, M. F. Sweeney, E. Missov, L. D. Joyce, R. John, and R. C. Prielipp Acute Left Atrial Thrombus After Recombinant Factor VIIa Administration During Left Ventricular Assist Device Implantation in a Patient with Heparin-Induced Thrombocytopenia Anesth. Analg., February 1, 2008; 106(2): 404 - 408. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Merry Focus on Thrombin: Alternative Anticoagulants Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2007; 11(4): 256 - 260. [Abstract] [PDF] |
||||
![]() |
A. Koster, T. Hentschel, T. Groman, H. Kuppe, R. Hetzer, S. Harder, and K.-G. Fischer Argatroban anticoagulation for renal replacement therapy in patients with heparin-induced thrombocytopenia after cardiovascular surgery J. Thorac. Cardiovasc. Surg., May 1, 2007; 133(5): 1376 - 1377. [Full Text] [PDF] |
||||
![]() |
R. L. Cain, B. D. Spiess, M. Nelson, A. Deanda Jr, H. L. McCarthy, and J. A. Green Bivalirudin Anticoagulation for a Patient with Hypercoagulable Immune Syndromes Undergoing Mitral Valve Surgery Ann. Thorac. Surg., June 1, 2006; 81(6): 2308 - 2310. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Koster, D. Chew, F. Merkle, M. Gruendel, M. Jurmann, H. Kuppe, and R. Oertel Extracorporeal Elimination of Large Concentrations of Tirofiban by Zero-Balanced Ultrafiltration During Cardiopulmonary Bypass: An In Vitro Investigation Anesth. Analg., October 1, 2004; 99(4): 989 - 992. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Stratmann, A. M. deSilva, E. E. Tseng, J. Hambleton, M. Balea, A. J. Romo, M. J. Mann, N. L. Achorn, W. F. Moskalik, and C. W. Hoopes Reversal of Direct Thrombin Inhibition After Cardiopulmonary Bypass in a Patient with Heparin-Induced Thrombocytopenia Anesth. Analg., June 1, 2004; 98(6): 1635 - 1639. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Green, C. L. Cooper, O. A. Falcucci, A. Safwat, T. Slaughter, B. D. Spiess, and V. G. Nielsen Argatroban for Off-Pump Coronary Artery Bypass Surgery * Response Anesth. Analg., October 1, 2003; 97(4): 1201 - 1202. [Full Text] [PDF] |
||||
|